VIDEO: Faricimab shows ‘amazing’ outcomes in underrepresented patients with DME
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema.
The multicenter trial enrolled patients from underrepresented groups who identified as Black/African American and Hispanic/Latino American. Patients received six monthly injections of faricimab followed by an injection every other month out to 1 year. The results were “amazing,” according to Brown, of Retina Consultants of Texas in San Antonio.
“Consistently, they had good visual recovery,” he said. “All groups gained vision. The vision gains tended to occur early in the study but continued on into the 1-year timepoint.”
Collapse
Brown J, et al. Treatment response and safety of faricimab in underrepresented patients with DME: Year 1 results from Elevatum in the US. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Read more about
Click Here to Manage Email Alerts